Louis  Brenner net worth and biography

Louis Brenner Biography and Net Worth

Louis Brenner, M.D., has served as Chief Executive Officer of Allena since February 2019 and as President since February 2017. He previously served as Chief Operating Officer from April 2015 to January 2019. 

Dr. Brenner has more than a decade of industry leadership experience, including pharmaceutical development strategy, regulatory affairs, business development and commercialization. Prior to joining Allena, Dr. Brenner served as Chief Medical Officer at Idera Pharmaceuticals, Chief Medical Officer at Radius Health, and Senior Vice President at AMAG Pharmaceuticals. He began his industry career at Genzyme Corporation. In these roles, he led successful product development programs for medicines that are currently marketed in the renal and metabolic areas. 

He holds an M.D. from Duke University, an M.B.A. from Harvard Business School and a B.S. from Yale University, He completed his residency in internal medicine at Brigham and Women’s Hospital and his fellowship in nephrology at Brigham and Women’s Hospital and Massachusetts General Hospital. Dr. Brenner holds a clinical appointment at Brigham and Women’s Hospital.

What is Louis Brenner's net worth?

The estimated net worth of Louis Brenner is at least $0.00 as of May 10th, 2021. Dr. Brenner owns 203,322 shares of Allena Pharmaceuticals stock worth more than $0 as of April 25th. This net worth evaluation does not reflect any other investments that Dr. Brenner may own. Additionally, Dr. Brenner receives a salary of $576,860.00 as COO at Allena Pharmaceuticals. Learn More about Louis Brenner's net worth.

How old is Louis Brenner?

Dr. Brenner is currently 52 years old. There are 5 older executives and no younger executives at Allena Pharmaceuticals. Learn More on Louis Brenner's age.

What is Louis Brenner's salary?

As the COO of Allena Pharmaceuticals, Inc., Dr. Brenner earns $576,860.00 per year. Learn More on Louis Brenner's salary.

How do I contact Louis Brenner?

The corporate mailing address for Dr. Brenner and other Allena Pharmaceuticals executives is ONE NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA, 02462. Allena Pharmaceuticals can also be reached via phone at (617) 467-4577 and via email at [email protected]. Learn More on Louis Brenner's contact information.

Has Louis Brenner been buying or selling shares of Allena Pharmaceuticals?

Louis Brenner has not been actively trading shares of Allena Pharmaceuticals during the last quarter. Most recently, Louis Md Brenner sold 25,215 shares of the business's stock in a transaction on Monday, May 10th. The shares were sold at an average price of $1.11, for a transaction totalling $27,988.65. Following the completion of the sale, the chief operating officer now directly owns 203,322 shares of the company's stock, valued at $225,687.42. Learn More on Louis Brenner's trading history.

Louis Brenner Insider Trading History at Allena Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/10/2021Sell25,215$1.11$27,988.65203,322View SEC Filing Icon  
12/17/2020Sell103,116$1.36$140,237.76144,816View SEC Filing Icon  
See Full Table

Louis Brenner Buying and Selling Activity at Allena Pharmaceuticals

This chart shows Louis Md Brenner's buying and selling at Allena Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Allena Pharmaceuticals Company Overview

Allena Pharmaceuticals logo
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $0.07
Low: $0.02
High: $0.16

2 Week Range

Now: N/A

Volume

96,558 shs

Average Volume

15,688,501 shs

Market Capitalization

$37,000.00

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.13